KaloCyte develops ErythroMer, a first‑in‑class dried, shelf‑stable red blood cell substitute that is reconstituted with water for use in ambulances, on the battlefield, or during prolonged emergencies. Preclinical data reportedly show ErythroMer safely emulates the oxygen‑carrying function of red blood cells. The company recently concluded a pre‑IND meeting with the U.S. Food and Drug Administration and says the New York Blood Center investment will support operational scale‑up as it prepares for human trials. KaloCyte is focused on raising a Series A equity round expected to close by late 2022 to fund IND‑enabling studies and Phase 1 clinical trials for ErythroMer’s primary indication as an oxygen carrier when perishable blood is unavailable. The company is backed by over $10M in investor and federal grant funding and positions ErythroMer for an estimated $7 billion U.S. market of unmet need from traumatic blood loss. KaloCyte is developing ErythroMer, an artificial red blood cell substitute intended for use when stored red blood cells are unavailable, such as treating trauma. The company is described as preclinical-stage. Less than a year after relocating its headquarters to Baltimore, KaloCyte expanded its local team. The firm announced a new investment from Maryland-based backers as part of a larger funding round. The article highlights the Maryland Momentum Fund’s support and praises the company’s engineering approach and team. No operating metrics (revenue/users) or clinical timelines were reported in the article.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2020